What records are connected here?
- Evidence lanes
- 2
- Source years
- 4
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
In clinical trials1,2,4Evidence: Large human trialsMetabolic and weight · Heart and blood vessels
Also called HM11260C2
Efpeglenatide is a GLP-1 receptor agonist built from an exendin-4 analogue joined, through a polyethylene glycol linker, to part of a human antibody (the IgG4 Fc fragment).2,3 In the AMPLITUDE-O trial of 4,076 adults with type 2 diabetes and heart or kidney disease, it lowered the rate of major cardiovascular events (7.0% versus 9.2% on placebo) and of kidney outcomes over about 1.8 years.3 No FDA approval is reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,4,6
| What it is | An exendin-4 analogue linked by polyethylene glycol to a human IgG4 Fc fragment, also coded HM11260C, according to FDA’s substance registry.2 |
|---|---|
| FDA status | Not FDA-approved. No FDA approval is reported in the sources reviewed here, and a phase 3 trial in type 2 diabetes is registered as recruiting.1,2 |
| Human evidence | One large randomized, placebo-controlled cardiovascular outcomes trial, AMPLITUDE-O, in 4,076 adults with type 2 diabetes.3 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Efpeglenatide is a modified exendin-4, a GLP-1 receptor agonist peptide, attached by a polyethylene glycol linker to the Fc fragment of a human IgG4 antibody. FDA’s substance registry also lists the codes HM11260C and the name langlenatide.2
The AMPLITUDE-O report describes it as an exendin-based GLP-1 receptor agonist, structurally different from the GLP-1 drugs that resemble human GLP-1.3
Like other GLP-1 receptor agonists it activates the GLP-1 receptor, which FDA’s substance registry records as its target.2
AMPLITUDE-O enrolled 4,076 adults with type 2 diabetes and either a history of cardiovascular disease or current kidney disease plus another risk factor, and randomly assigned them to efpeglenatide or placebo.3
Over a median of 1.81 years, a major cardiovascular event (heart attack, stroke or cardiovascular death) occurred in 7.0% of those on efpeglenatide and 9.2% on placebo, a hazard ratio of 0.73. A composite kidney outcome occurred in 13.0% and 18.4%.3
Diarrhoea, constipation, nausea, vomiting and bloating were more common with efpeglenatide than with placebo.3
Evidence-strength label: Large randomized human trials. How this label is assigned
None of the sources reviewed here reports an approval of efpeglenatide by FDA.2,4
ClinicalTrials.gov lists a phase 3 trial of efpeglenatide in type 2 diabetes as recruiting in its May 13, 2026 record.1
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list efpeglenatide.4
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Efpeglenatide is not among them.5,6
Its effects beyond the AMPLITUDE-O population, which was limited to adults with type 2 diabetes at high cardiovascular or kidney risk.3
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Efpeglenatide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Efpeglenatide are a bounded selection, not every registration or paper about Efpeglenatide. For the years before Efpeglenatide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Efpeglenatide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Efpeglenatide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
In clinical trials; not FDA-approved. In AMPLITUDE-O, major cardiovascular events occurred in 7.0% of adults with type 2 diabetes on efpeglenatide and 9.2% on placebo. Efpeglenatide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
In clinical trials; not FDA-approved. In AMPLITUDE-O, major cardiovascular events occurred in 7.0% of adults with type 2 diabetes on efpeglenatide and 9.2% on placebo. Efpeglenatide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date July 7, 2026
ClinicalTrials.gov record NCT06174779↗Added to PeptideScanner November 16, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT06174779↗Source date July 7, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT07379333↗Source date May 13, 2026Literature metadata · added November 16, 2026
Population pharmacokinetics of efpeglenatide in individuals with obesity and with type 2 diabetes.↗Source date December 19, 2025PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
6 of 6 selected trial records include at least one phase value; 6 of 6 include a status value in the retained structured contract.
1 of 1 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT01093729 at 2026-11-16T17:34:46.889Z. Its registry update date was 2014-02-07, and PeptideScanner's reviewed identity mapping was efpeglenatide.
PeptideScanner retained ClinicalTrials.gov record NCT01452451 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide.
PeptideScanner retained ClinicalTrials.gov record NCT02075281 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide.
1 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span February 7, 2014 to July 7, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06174779 at 2026-11-16T17:34:46.889Z. Its registry update date was 2026-07-07, and PeptideScanner's reviewed identity mapping was efpeglenatide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07379333 at 2026-11-16T17:34:46.889Z. Its registry update date was 2026-05-13, and PeptideScanner's reviewed identity mapping was efpeglenatide.↗
Literature metadata
PubMed lists PMID 41403449 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2025-12-01 (day precision). PeptideScanner associated the retained record with the identity slug efpeglenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01452451 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02075281 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02081118 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01093729 at 2026-11-16T17:34:46.889Z. Its registry update date was 2014-02-07, and PeptideScanner's reviewed identity mapping was efpeglenatide.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
ClinicalTrials.gov · Official source · Source checked November 16, 2026
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
The New England Journal of Medicine · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026